1415689-71-2Relevant academic research and scientific papers
6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors
Zhao, Xue Zhi,Maddali, Kasthuraiah,Smith, Steven J.,Métifiot, Mathieu,Johnson, Barry C.,Marchand, Christophe,Hughes, Stephen H.,Pommier, Yves,Burke Jr., Terrence R.
, p. 7309 - 7313 (2013/02/21)
Although an extensive body of scientific and patent literature exists describing the development of HIV-1 integrase (IN) inhibitors, Merck's raltegravir and Gilead's elvitegravir remain the only IN inhibitors FDA-approved for the treatment of AIDS. The em
